Molecular targets for the rational design of antiepileptic drugs and related neuroprotective agents

Medicinal Research Reviews

Volumn 17, Issue 6, 1997, Pages 537-572

  Lin, Zhaiwei ^a,b   Kadaba, Pankaja K ^a,c,d  

^a K and K Biosciences Inc   (United States)

^b TULANE UNIVERSITY   (United States)

^c UNIVERSITY OF DELHI   (India)

^d University of Kentucky   (United States)

Author keywords

Antiepileptic drugs; Rational design; Receptor targets

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1 (4 CHLOROPHENYL) 4,5 DIHYDRO 5 (4 PYRIDYL) 1H 1,2,3 TRIAZOLE; 4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; AMINO ACID RECEPTOR AFFECTING AGENT; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; BARBITURIC ACID; BENZODIAZEPINE; CARBONATE DEHYDRATASE; DECAHYDRO 6 (1H TETRAZOL 5 YL) 3 ISOQUINOLINECARBOXYLIC ACID; DIZOCILPINE; EXCITATORY AMINO ACID RECEPTOR; GLUTAMATE DECARBOXYLASE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE RECEPTOR; KAINIC ACID RECEPTOR; MAGNESIUM; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; PHENCYCLIDINE; PICROTOXIN; POLYAMINE; SIGMA OPIATE RECEPTOR; STEROID; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC;

BINDING SITE; DRUG DESIGN; DRUG MECHANISM; DRUG RECEPTOR BINDING; EPILEPSY; EPILEPTOGENESIS; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; NEUROTRANSMISSION; NONHUMAN; ORAL DRUG ADMINISTRATION; RECEPTOR AFFINITY; REVIEW;

ANIMALS; ANTICONVULSANTS; DRUG DESIGN; HUMANS; NEUROPROTECTIVE AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030724836     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1128(199711)17:6<537::AID-MED3>3.0.CO;2-2     Document Type: Review

References (260)

1. F.M. Forster, Ed., Report of the Panel on Epilepsy, University of Wisconsin Press, Madison, WI, 1961, p. 91.
2. Commission on Classification and Terminology of the International League Against Epilepsy, "Proposal for Revised Clinical and Electroencephalographic Classification of Epileptic Seizures," Epilepsia, 22, 489 (1981).
3. M. A. Rogawski and R. J. Porter, Pharmacol. Rev., 42, 223 (1990).
4. S. Chokroverty, in Management of Epilepsy, S. Chokroverty, Ed., Butterworth-Heinemann, Newton, MA, 1996, p. 345.
5. W. A. Hauser and D. C. Hesdorffer, Epilepsy: Frequency, Causes, and Consequences, Demos Publications, New York, 1990, p. 1.
6. R. J. Gumnit, Ed., The Epilepsy Handbook: The Practical Management of Seizures, 2nd ed., Raven Press, New York, 1995.
7. J. M. Pellock, Epilepsia, 35 (suppl. 4), S11 (1994).
8. C. Shin and J. O. McNamara, Ann. Rev. Med., 45, 379 (1994).
9. R. L. Macdonald and K. M. Kelly, Epilepsia, 35 (suppl. 4), S41 (1994).
10. Lilly Research Laboratories, "Phenobarbital," in Physician's Desk Reference, D. W. Sifton, Ed., Medical Economics Data Production Company, Montvale, NJ, 1994, pp. 1255-1257.
11. R. H. Mattson and J. A. Cramer, "Phenobarbital: Toxicity," in Antiepileptic Drugs, D. M. Woodbury, J. K. Penry, and C. E. Pippenger, Eds., Raven Press, New York, 1982, pp. 351-363.
12. W. D. Hooper and M. J. Eadie, "Mephobarbital," in The Medical Treatment of Epilepsy, S. R. Resor, Jr. and H. Kutt, Eds., Marcel Dekker, New York, 1992, pp. 363-369.
13. Parke-Davis, "Dilantin" (prescription drug labeling), in Physician's Desk Reference, D. W. Sifton, Ed., Medical Economics Data Production Company, Montvale, NJ, 1994, pp. 1730-1735.
14. M. Dam, "Phenytoin: Toxicity," in Antiepileptic Drugs, D. M. Woodbury, J. K. Penry, and C. E. Pippenger, Eds., Raven Press, New York, 1982, pp. 247-256.
15. F. E. Dreifuss, "Ethosuximide: Toxicity," in Antiepileptic Drugs, D. M. Woodbury, J. K. Penry, and C. E. Pippenger, Eds., Raven Press, New York, 1982, pp. 647-653.
16. A. L. Sherwin, "Ethosuximide," in The Treatment of Epilepsy: Principles and Practices, E. Wyllie, Ed., Lea & Febiger, Philadelphia, 1993, pp. 923-929.
17. R. W. Homan and H. C. Rosenberg, "Benzodiazepines," in The Treatment of Epilepsy: Principles and Practices, E. Wyllie, Ed., Lea & Febiger, Philadelphia, 1993, pp. 932-949.
18. H. Kutt, "Diazepam," in The Medical Treatment of Epilepsy, S. R. Resor, Jr. and H. Kutt, Eds., Marcel Dekker, New York, 1992, pp. 341-343.
19. Abbott Laboratories, "Depakene" (prescription drug labeling), in Physicians' Desk Reference, D. W. Sifton, Ed., Medical Economics Data Production Company, Montvale, NJ, 1994, pp. 411-415.
20. J. C. Dean, "Valproate," in The Treatment of Epilepsy: Principles and Practices, E. Wyllie, Ed., Lea & Febiger, Philadelphia, 1993, pp. 915-921.
21. R. E. Ramsay, Neurology, 44 (suppl. 5), S23 (1994).
22. F. Matsuo, D. Bergen, E. Faught, J. A. Messenheimer, A. T. Dren, G. D. Rudd, and C. G. Lineberry, Neurology, 43, 2284 (1993).
23. J. W. Sander, Y. M. Hart, M. D. Trimble, and S. D. Shorvon, Epilepsia, 32 (suppl. 1), 12 (1992).
24. R. Sachdeo, R. Leroy, G. Krauss, P. Green, M. Drake, I. Leppik, V. Shu, G. Ringham, and K. Sommerville, Neurology, 45 (suppl. 4), 202 (1995).
25. S. Chokroverty, in Management of Epilepsy, S. Chokroverty, Ed., Butterworth-Heinemann, Newton, MA, 1996, pp. 10-15.
26. J. F. Annergers, "The Epidemiology of Epilepsy," in The Treatment of Epilepsy: Principles and Practices, E. Wyllie, Ed., Lea & Febiger, Philadelphia, 1993, p. 157.
27. C. Wasterlain, "Epileptic Seizures," in Basic Neurochemistry, G. J. Siegel, B. W. Agranoff, R. W. Albers, and P. B. Molinoff, Eds., Raven Press, New York, 1989, p. 798.
28. D. G. Nicholls, in Excitatory Amino Acids and Synaptic Transmission, H. Wheal and A. Thomson, Eds., Academic Press, Sandiego, 1995, pp. 1-17.
29. B. E. Alger et al., in Neurotransmitter Actions in the Vertebrate Nervous System, M. A. Rogawski and J. L. Barker, Eds., Plenum Press, New York, 1985, pp. 1-100.
30. E. DeRobertis, G. R. DeLores-Arnaiz, and M. Alberici, "Ultrastructural Neurochemistry," in Basic Mechanisms of the Epilepsies, H. H. Jasper et al., Eds., Little, Brown, and Co., Boston, 1969, pp. 137-158.
31. D. W. Choi, J. Neurosci., 7, 369 (1987).
32. D. W. Choi, Neuron, 1, 623 (1988).
33. A. Novelli, J. A. Reilly, P. G. Lysko, and R. C. Henneberry, Brain Res., 451, 205 (1988).
34. M. L. Mayer and G. L. Westbrook, Prog. Neurobiol., 28, 197 (1987).
35. P. B. Molinoff, K. Williams, D. B. Pritchett, and J. Zhong, in Prog. Brain Res., 100, Neuroscience: From the Molecular to the Cognitive, F. E. Bloom, Ed., Elsevier, New York, 1994, pp. 39-47.
36. R. C. Malenka, in Excitatory Amino Acids and Synoptic Transmission, H. Wheal and A. Thomson, Eds., Academic Press, San Diego, 1995, pp. 240-247.
37. S. Nakanishi, Science, 258, 597 (1992).
38. P. H. Seeburg, Trends Neurosci., 16, 359 (1993).
39. D. T. Monaghan, R. J. Bridges, and C. W. Cotman, Ann. Rev. Pharmacol. Toxicol., 29, 365 (1989).
40. M. Hollmann and S. Heinemann, Ann. Rev. Neurosci., 17, 31 (1994).
41. S. Nakanishi and M. Masu, Ann. Rev. Biophys. Biomol. Struct., 23, 319 (1994).
42. J. Willets, R. L. Balster, and J. D. Leander, Trends Pharmacol. Sci., 11, 423 (1990).
43. W. Haefely, J. R. Martin, and P. Schoch, Trends Pharmacol. Sci., 11, 452-456 (1990).
44. W. Haefely, M. Facklam, P. Schoch, J. R. Martin, E. P. Bonetti, J.-L. Moreau, F. Jenck, and J. G. Richards, Partial Agonists of Benzodiazepine Receptors for the Treatment of Epilepsy, Sleep, and Anxiety Disorders; GABAergic Synaptic Transmission, G. Biggio, A. Concas, and E. Costa, Eds., Raven Press, New York, 1992, pp. 379-394.
45. E. N. Petersen, L. H. Jensen, J. Diejer, and T. Honore, Pharmacopsychiatry, 19, 4 (1986).
46. M. L. Mayer and G. L. Westbrook, J. Physiol., 394, 501 (1987).
47. J. W. Olney, Drug Dev. Res., 17, 299 (1989).
48. G. Johnson, Ann. Rep. Med. Chem., 24, 41 (1989).
49. R. J. Porter and W. H. Pitlick, in Basic and Clinical Pharmacology, 4th ed., B. G. Katzung, Ed., Appleton & Lange, CA, 1989, pp. 287-303.
50. R. J. Porter, Epilepsia, 30, (suppl. 1), S 29-34 (1989).
51. D. T. Monaghan and C. W. Cotman, J. Neurosci., 5, 2909 (1985).
52. D. T. Monaghan and C. W. Cotman, Proc. Natl. Acad. Sci., 83, 7532 (1986).
53. M. Abou-Gharbia, S. Y. Ablordeppey, and R. A. Glennon, Ann. Rep. Med. Chem., 28, 1 (1993).
54. T.-P. Su, Crit. Revs. Neurobiol., 7, 187 (1993).
55. L. L. Iversen, Neurotransmissions, 10, 1 (1994).
56. P. L. Ornstein, D. D. Schoepp, M. B. Arnold, N. K. Augenstein, D. Lodge, J. D. Miller, J. Chambers, J. Campbell, J. W. Paschal, D. M. Zimmerman, and J. D. Leander, J. Med. Chem., 35, 3547 (1992).
57. S. Shuto, H. Takada, D. Mochizuki, R. Tsujita, Y. Hase, S. Ono, N. Shibuya, and A. Matsuda, J. Med. Chem., 38, 2964 (1995).
58. J.-H. Li, C. F. Bigge, R. M. Williamson, S. A. Borosky, M. G. Vartanian, and D. F. Ortwine, J. Med. Chem., 38, 1955 (1995).
59. Y. Gaoni, A. G. Chapman, N. Parvez, P. C.-K. Pook, D. E. Jane, and J. C. Watkins, J. Med. Chem. 37, 4288 (1994).
60. L. L. Martin, G. E. Lee, T. B. K. Lee, D. K. Rush, C. A. Wilmot, E. Paulus, U. Elben, J. J. Grome, E. P. Wiebking, K. A. Rudolphi, and P. Stoll, J. Med. Chem., 37, 3008 (1994).
61. P. L. Ornstein, D. D. Schoepp, M. B. Arnold, N. D. Jones, J. B. Deeter, D. Lodge, and J. D. Leander, J. Med. Chem., 35, 3111 (1992).
62. M. Kessler, T. Terramini, G. Lynch, and M. Baudry, J. Neurochem., 52, 1319 (1989).
63. R. L. Macdonald, N. M. Porter, and R. E. Twyman, Neurochem. Int., 16 (suppl. 1), 24 (1990).
64. W. Koek and F. C. Colpaert, "N-Methyl-D-aspartate Antagonism and Phencyclidine-like Activity: Behavioral Effects of Glycine Site Ligands," in Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection?, J.-M. Kamenka and E. F. Domino, Eds., CPP Books, Ann Arbor, MI, 1992, pp. 665-671.
65. J. W. Olney, J. Labruyere, and M. T. Price, Science, 244, 1360 (1989).
66. R. J. Hargreaves, M. Rigby, D. Smith, and R. G. Hill, Br. J. Pharmacol., 110, 36 (1993).
67. P. D. Leeson and L. L. Iversen, J. Med. Chem., 37, 4053 (1994).
68. R. W. Carling, P. D. Leeson, A. M. Moseley, J. D. Smith, K. Saywell, M. D. Tricklebank, J. A. Kemp, G. R. Marshall, A. C. Foster, and S. Grimwood, BioMed. Chem. Lett., 3, 65 (1993).
69. M. J. Croucher and H. F. Bradford, Neurosci. Lett., 118, 29 (1990).
70. A. M. MacLeod, S. Grimwood, C. Barton, L. Bristow, K. L. Saywell, G. R. Marshall, and R. G. Ball, J. Med. Chem., 38, 2239 (1995).
71. J. F. W. Keana, S. M. Kher, S. X. Cai, C. M. Dinsmore, A. G. Glenn, J. Guastella, J.-C. Huang, V. Ilyin, Y. Lu, P. L. Mouser, R. M. Woodward, and E. Weber, J. Med. Chem., 38, 4367 (1995).
72. J. A. Kemp and P. D. Leeson, Trends Pharmacol. Sci., 14, 20 (1993).
73. P. D. Leeson, B. J. Williams, M. Rowley, K. W. Moore, R. Baker, J. A. Kemp, T. Priestley, A. C. Foster, and E. A. Donald, BioMed. Chem. Lett., 3, 71 (1993).
74. J. A. Kemp, A. C. Foster, P. D. Leeson, T. Priestley, R. Tridgett, L. L. Iversen, and G. N. Woodruff, Proc. Nat. Acad. Sci., 85, 6547 (1988).
75. R. W. Carling, P. D. Leeson, K. W. Moore, J. D. Smith, C. R. Moyes, I. M. Mawer, S. Thomas, T. Chan, R. Baker, A. C. Foster, S. Grimwood, and J. A. Kemp, J. Med. Chem., 36, 3397 (1993).
76. E. H. F. Wong, A. R. Knight, and G. N. Woodruff, J. Neurochem., 50, 274 (1988).
77. W. F. Maragos, J. B. Penney, and A. B. Young, J. Neurosci., 8, 493 (1988).
78. R. W. Ransom and N. L. Deschenes, Synapse, 5, 294 (1990).
79. G. C. Yeh, D. W. Bonhaus, and J. O. McNamara, Mol. Pharmacol., 38, 14 (1990).
80. M. D. Tricklebank, L. Singh, R. J. Oles, C. Preston, and S. D. Iversen, Eur. J. Pharmacol., 167, 127 (1989).
81. B. S. Meldrum, Ed., Excitatory Amino Acid Antagonists, Blackwell, Oxford, 1991.
82. D. Lodge, "Ligands for NMDA Receptor Modulatory Sites," in Excitatory Amino Acid Receptors: Design of Agonists and Antagonists, P. Krogsgaard-Larsen and J. J. Hansen, Eds., Ellis Horwood, Chichester, 1992, pp. 201-215.
83. V. Kumar, P. M. Carabateas, J. A. Dority, Jr., W. G. Earley, J. P. Mallamo, C. Subramanyam, L. D. Aimone, B. Ault, D. L. D. Hudkins, and M. S. Miller, J. Med. Chem., 38, 1826 (1995).
84. A. H. Newman, K. Bevan, N. Bowery, and F. C. Tortella, J. Med. Chem., 35, 4135 (1992).
85. C. F. Bigge, T. C. Malone, S. J. Hays, G. Johnson, P. M. Novak, L. J. Lescosky, D. M. Retz, D. F. Ortwine, A. W. Probert, Jr., L. L. Coughenour, P. A. Boxer, L. J. Robichaud, L. J. Brahce, and J. L. Shillis, J. Med. Chem., 36, 1977 (1993).
86. K. R. Gee, P. Barmettler, M. R. Rhodes, R. N. McBurney, N. L. Reddy, L.-Y. Hu, R. E. Cotter, P. N. Hamilton, E. Weber, and J.F.W. Keana, J. Med. Chem., 36, 1938 (1993).
87. R. Ransom and N. Stec, J. Neurochem., 51, 830 (1988).
88. A. Sacaan and K. Johnson, Mol. Pharmacol., 37, 572 (1990).
89. B. Scatton, P. Avenet, J. Benavides, C. Carter, D. Duverger, A. Oblin, G. Perrault, D. Sanger, and H. Schoemaker, "Neuroprotective Potential of the Polyamine Site-Directed NMDA Receptor Antagonists-Ifenprodil and Eliprodil," in Direct and Allosteric Control of Glutamate Receptors, M. G. Palfreyman, I. J. Reynolds, and P. Skolnick, Eds., CRC Press, Boca Raton, 1994, pp. 139-154.
90. L.-M. Zhou, X.-S. He, G. Li, B. R. de Costa, and P. Skolnick, J. Med. Chem., 38, 4891 (1995).
91. J. Carter, J. Benvides, P. Legendre, J. D. Vincent, F. Noel, F. Thuret, K. G. Lloyd, S. Arbilla, B. Zivkovic, E. T. J. MacKenzie, B. Scatton, and S. Z. Langer, J. Pharmacol. Exp. Ther., 247, 1222 (1988).
92. P. Legendre and G. L. Westbrook, Mol. Pharmacol., 40, 289 (1991).
93. C. Dana, J. Benavides, H. Schoemaker, and B. Scatton, Neurosci. Lett., 125, 45 (1991).
94. B. R. de Costa, K. C. Rice, W. D. Bowen, A. Thurkauf, R. B. Rothman, L. Bard, A. E. Jacobson, L. Radesca, P. C. Contreras, N. M. Gray, I. Daly, S. Iyengar, D. T. Flinn, S. Varizani, and J. M. Walker, J. Med. Chem., 33, 3100 (1990).
95. E. W. Karbon, R. L. Patch, M. J. Pontecorvo, and J. W. Ferkany, Eur. J. Pharmacol., 176, 247 (1990).
96. I. J. Reynolds and R. J. Miller, Eur. J. Pharmacol., 151, 103 (1988).
97. I. J. Reynolds and R. J. Miller, Brit. J. Pharmacol., 95, 95102 (1988).
98. G. Wolf et al., Neurosci. Lett., 117, 207 (1990).
99. J.-H. J. Cha, J. T. Greenamyre, E. O. Nielsen, J. B. Penney, and A. B. Young, J. Neurochem., 51, 469 (1988).
100. T. Honore and J. Drejer, J. Neurochem., 51, 457 (1988).
101. T. Honore, J. Drejer, E. O. Nielsen, and M. Nielsen, Biochem. Pharmacol., 38, 3207 (1989).
102. P. L. Ornstein, M. B. Arnold, N. K. Augenstein, D. Lodge, J. D. Leander, and D. D. Schoepp, J. Med. Chem., 36, 2046 (1993).
103. A. M. Buchan, D. Xue, Z.-G. Huang, K. H. Smith, and H. Lesiuk, NeuroReport, 2, 473 (1991).
104. J. Ohmori, S. Sakamoto, H. Kubota, M. Shimizu-Sasamata, M. Okada, S. Kawasaki, K. Hidaka, J. Togami, T. Furuya, and K. Murase, J. Med. Chem., 37, 467 (1994).
105. S. E. Smith, N. Durmuller, and B. S. Meldrum, Eur. J. Pharmacol., 201, 179 (1991).
106. P. L. Ornstein, M. B. Arnold, N. K. Allen, J. D. Leander, J. P. Tizzano, D. Lodge, and D. D. Schoepp, J. Med. Chem., 38, 4885 (1995).
107. P. L. Ornstein, M. B. Arnold, N. K. Allen, T. Bleisch, P. S. Borromeo, C. W. Lugar, J. D. Leander, D. Lodge, and D. D. Schoepp, J. Med. Chem., 39, 2219 (1996).
108. J. C. Pelletier, D. P. Hesson, K. A. Jones, and A.-M. Costa, J. Med. Chem., 39, 343 (1996).
109. J. C. Watkins, P. Krogsgaard-Larsen, and T. Honore, Trends Pharmacol. Sci., 11, 25 (1990).
110. J. T. Coyle, J. Ferkany, R. Zaczek, J. Slevin, and K. Retz, "Kainic Acid: Insights Into its Receptor-Mediated Neurotoxic Mechanisms," in Excitotoxins, K. Fuxe, P. Roberts, and R. Schwarcz, Eds., Plenum Press, New York, 1984, pp. 112-121.
111. T. H. Johansen, J. Drejer, F. Watjen, and E. O. Nielsen, Eur. J. Pharmacol. Mol. Pharmacol. Sect., 246, 195 (1993).
112. Z.-Q. Gu, D. P. Hesson, J. C. Pelletier, and M.-L. Maccecchini, J. Med. Chem., 38, 2518 (1995).
113. T. Abe, H. Sugihara, H. Nawa, R. Shigemoto, N. Mizuno, and S. Nakanishi, J. Biol. Chem., 267, 13361 (1992).
114. N. Okamoto, S. Hori, C. Akazawa, Y. Hayashi, R. Shigemoto, N. Mizuno, and S. Nakanishi, J. Biol. Chem., 269, 1231 (1994).
115. M. Hollman and S. Heinemann, Ann. Rev. Neurosci., 17, 31 (1994).
116. D. D. Schoepp and P. J. Conn, Trends Pharmacol. Sci., 14, 13 (1993).
117. J.-P. Pin and R. Duvoisin, Neuropharmacology, 34, 1 (1995).
118. T. Knopfel, R. Kuhn, and H. Allgeier, J. Med. Chem., 38, 1417 (1995).
119. S. Charpak, B. H. Gahwiler, K. Q. Do, and T. Knopfel, Nature, 347, 765 (1990).
120. Y. Hayashi, N. Sekiyama, S. Nakanishi, D. E. Jane, D. C. Sunter, E. F. Birse, P. M. Udvarhelyi, and J. C. Watkins, J. Neurosci., 14, 3370 (1994).
121. F. Nicoletti, J. L. Meek, M. J. Indarola, D. M. Chuang, B. L. Roth, and E. Costa, J. Neurochem., 46, 40 (1986).
122. J.-H. J. Cha, R. L. Makowiec, J. B. Penney, and A. B. Young, Neurosci. Lett., 113, 78 (1990).
123. R. Pellicciari, M. Raimondo, M. Marinozzi, B. Natalini, G. Costantino, and C. Thomsen, J. Med. Chem., 39, 2874 (1996).
124. M. V. Catania, Z. Hollingsworth, J. B. Penney, and A. B. Young, NeuroReport, 4, 311 (1993).
125. M. V. Catania, H. de Socarraz, J. B. Penney, and A. B. Young, Mol. Pharmacol., 45, 626 (1994).
126. Y. Tanabe, A. Nomura, M. Masu, R. Shigemoto, N. Mizuno, and S. Nakanishi, J. Neurosci., 13, 1372 (1993).
127. J. A. Saugstad, J. M. Kinzie, E. R. Mulvihill, T. P. Segerson, and G. L. Westbrook, Mol. Pharmacol., 45, 367 (1994).
128. Y. M. Lu and T. Knopfel, Soc. Neurosci. Abstr., 20, (1994).
129. R. Pellicciari, M. Marinozzi, B. Natalini, G. Costantino, R. Luneia, G. Giorgi, F. Moroni, and C. Thomsen, J. Med. Chem. 39, 2259 (1996).
130. J. A. Monn, M. J. Valli, B. G. Johnson, C. R. Salhoff, R. A. Wright, T. Howe, A. Bond, D. Lodge, L. A. Spangle, J. W. Paschal, J. B. Campbell, K. Griffey, J. P. Tizzano, and D. D. Schoepp, J. Med. Chem., 39, 2990 (1996).
131. E. A. Cavelheiro, J. Lehmann, and L. Turski, Eds., Frontiers in Excitatory Amino Acid Research, Alan R. Liss, New York, 1988.
132. P. R. Maycox, J. W. Hell, and R. Jahn, Trends Neurosci., 13, 83 (1990).
133. P. R. Maycox, T. Deckworth, J. W. Hell, and R. Jahn, J. Biol. Chem., 263, 15423 (1988).
134. J. R. Ames, P. Kovacic, P. K. Kadaba, and P. F. Kiser, Epilepsia, 33, 936 (1992).
135. P. K. Kadaba, P. J. Stevenson, I. P-Nnane, and L. A. Damani, Bioorg. Med. Chem., 4, 165 (1996).
136. P. K. Kadaba, Drugs Future, 15, 1013 (1990).
137. P. K. Kadaba and J. T. Slevin, Epilepsia, 29, 330 (1988).
138. D. R. Curtis and G.A.R. Johnston, Ergeb. Physiol., 69, 97 (1974).
139. F. Fonnum, Ed., Amino Acids as Chemical Transmitters, Plenum Press, New York, 1978.
140. P. Krogsgaard-Larsen, J. Scheel-Kruger, and H. Kofod, Eds., GABA-Neurotransmitters: Pharmacochemical, Biochemical, and Pharmacological Aspects, Munksgaard, Copenhagen, 1979.
141. R. W. Olsen and J. C. Venter, Eds., Benzodiazepine/GABA Receptors and Chloride Channels: Structural find Functional Properties, Receptor Biochemistry and Methodology, Vol. 5, Alan R. Liss, New York, 1986.
142. F. A. Stephenson, Biochem. J., 249, 21 (1988).
143. A Receptors by Benzodiazepine Receptor Ligands," in Allosteric Modulation of Amino Acid Receptors: Therapeutic Implications, E. A. Barnard and E. Costa, Eds., Raven Press, New York, 1989, pp. 47-69.
144. A Receptor in the Central Nervous System," in Allosteric Modulations of Amino Acid Receptors: Therapeutic Implications, E. A. Barnard and E. Costa, Eds., Raven Press, New York, 1989, pp. 31-46.
145. N. G. Bowery, in The GABA Receptors, S. J. Enna, Ed., Humana Press, Clifton, NJ, 1983, p. 177.
146. K. Kato, M. Goto, and H. Fukuda, Gen. Pharmacol., 13, 445 (1982).
147. N. G. Bowery, D. R. Hill, A. L. Hudson, G. W. Price, M. J. Turnbull, and G. P. Wilkin, in Actions and Interactions of GABA and Benzodiazepines, N. G. Bowery, Ed., Raven Press, New York, 1984, p. 81.
148. P. B. Molinoff, K. Williams, D. B. Pritchett, and J. Zhong, in Prog. Brain Res., 100, Neuroscience: From the Molecular to the Cognitive, F. E. Bloom, Ed., Elsevier, New York, 1994, pp. 61-65.
149. R. W. Olsen, J. Neurochem., 37, 1 (1981).
150. E. A. Barnard, M. G. Darlison, N. Fujita, T. A. Glencorse, E. S. Levitan, V. Reale, P. R. Schofield, P. H. Seeburg, M. D. Squire, and F. A. Stephenson, in Neuroreceptors and Signal Transduction, S. Kito, T. Segawa, K. Kuriyama, M. Tohyama, and R. W. Olsen, Eds., Plenum Press, New York, 1988, pp. 31-47.
151. R. W. Olsen and A. J. Tobin, Fed. Am. Soc. Exp. Biol. J., 4, 1469 (1990).
152. D. I .B. Kerr and J. Ong, Med. Res. Rev., 12, 593 (1992).
153. A. B. Young and J. B. Penney, Jr., in Receptors in the Human Nervous System, F.A.O. Mendelsohn and G. Paxinos, Eds., Academic Press, San Diego, 1991, pp. 9-47.
154. J. M. Kane, M. A. Staeger, C. R. Dalton, F. P. Miller, M. W. Dudley, A. M .L. Ogden, J. H. Kehne, H. J. Ketteler, T. C. McCloskey, Y. Senyah, P. A. Chmielewski, and J. A. Miller, J. Med. Chem., 37, 125 (1994).
155. E. M. Peterson, K. Xu, K. D. Holland, A. C. McKeon, S. M. Rothman, J. A. Ferrendelli, and D. F. Covey, J. Med. Chem., 37, 275 (1994).
156. D. R. Burt and G. I. Kamatchi, FASEB J., 5, 2916 (1991).
157. D. B. Pritchett and P. H. Seeburg, Proc. Natl. Acad. Sci., 88, 1421 (1991).
158. C. R. Gardner, Prog. Neurobiol., 31, 425 (1988).
159. C. Braestrup and M. Nielsen, in Receptor Biochemistry and Methodology, R. W. Olsen and J. C. Venter, Eds., Alan R. Liss, Inc., New York, 1986, Vol. 5, p. 167.
160. W. Haefely, E. Kyburz, M. Gerecke, and H. Mohler, "Recent Advances in the Molecular Pharmacology of Benzodiazepine Receptors and in the Structure-Activity Relationships of Their Agonists and Antagonists," in Advances in Drug Research, B. Testa, Ed., Academic Press, New York, 1985, Vol. 14, pp. 165-322.
161. B. E. Maryanoff, W. Ho, D. F. McComsey, A. B. Reitz, P. P. Grous, S. O. Nortey, R. P. Shank, B. Dubinsky, R. J. Taylor, Jr., and J. F. Gardocki, J. Med. Chem., 38, 16 (1995).
162. E. J. Jacobsen, R. E. Tenbrink, L. S. Stelzer, K. L. Belonga, D. B. Carter, H. K. Im, W. B. Im, V. H. Sethy, A. H. Tang, P. F. Von Voigtlander, and J. D. Petke, J. Med. Chem., 39, 158 (1996).
163. J. Guillon, M. Daoust, D. Radulovic, M. Boulouard, P. Dallemagne, E. Legrand, S. Rault, M. A. Quermonne, and M. Robba, Eur. J. Med. Chem., 31, 335 (1996).
164. S. Takada, T. Sasatani, N. Chomei, M. Adachi, T. Fujishita, M. Eigyo, S. Murata, K. Kawasaki, and A. Matsushita, J. Med. Chem., 39, 2844 (1996).
165. J. C. Eccles, R. F. Schmidt, and W. D. Willis, J. Physiol. (London), 168, 500 (1963).
166. R. F. Schmidt, Pfuergers Arch., 277, 325 (1963).
167. M. Willow and G. A. R. Johnston, J. Neurosci., 1, 364 (1981).
168. M. Willow and G. A. R. Johnston, J. Neurochem., 37, 1291 (1981).
169. R. L. Macdonald and J. L. Barker, Neurology, 29, 432 (1979).
170. L. M .F. Leeb-Lundberg and R. W. Olsen, Mol. Pharmacol., 23, 315 (1983).
171. L. M. F. Leeb-Lundberg and R. W. Olsen, Mol. Pharmacol., 21, 320 (1982).
172. J. A. Vida, "Anticonvulsants," in Principles of Medicinal Chemistry, W. O. Foye, T. L. Lemke, and D. A. Williams, Eds., Williams & Wilkins, Philadelphia, PA, 1995, pp. 182-198.
173. R. F. Squires, J. E. Casida, M. Richardson, and E. Saedrup, Mol. Pharmacol., 23, 326 (1983).
174. M. G. Wong and P. R. Andrews, Eur. J. Med. Chem., 24, 323 (1989).
175. N. G. Bowery, J. F. Collins, R. G. Hill, and S. Pearson, Br. J. Pharmacol., 57, 435 (1976).
176. J. E. Casida, M. Eto, A. D. Moscioni, J. L. Engel, D. S. Milbrath, and J. G. Verkade, Toxicol. Appl. Pharmacol., 36, 261 (1976).
177. C. L. Brown and I. L. Martin, Eur. J. Pharmacol., 106, 167 (1985).
178. P. A. Reddy, B. C. H. Hsiang, T. N. Latifi, M. W. Hill, K. E. Woodward, S. M. Rothman, J. A. Ferrendelli, and D. F. Covey, J. Med. Chem., 39, 1898 (1996).
179. D. J. Canney, K. D. Holland, J. A. Levine, A. C. Mckeon, J. A. Ferrendelli, and D. F. Covey, J. Med. Chem., 34, 1460 (1991).
180. K. J. Child, J. P. Curie, B. Davis, M. G. Dodds, D. R. Pearce, and D. J. Twissell, Br. J. Anaes., 43, 2 (1971).
181. M. D. Majewska, Biochem. Pharmacol., 36, 3781 (1987).
182. J. J. Lambert, J. A. Peters, and G. A. Cottrell, Trends Pharmacol. Sci., 8, 224 (1987).
183. L. Gymerk, J. Iriarte, and P. Crabbe, J. Med. Chem., 11, 117 (1968).
184. M. D. Majewska, N. L. Harrison, R. D. Schwartz, J. L. Barker, and S. M. Paul, Science, 232, 1004 (1986).
185. J. Bormann, Trend. Neurosci., 11, 112 (1988).
186. N. G. Bowery, Trends Pharmacol. Sci., 10, 401 (1989).
187. R. Andrade, R. C. Malenka, and R. A. Nicoll, Science, 234, 1261 (1986).
188. P. Dutar and R. A. Nicoll, Neuron, 1, 585 (1988).
189. K. Dunlap, Br. J. Pharmacol., 74, 579 (1981).
190. A. C. Dolphin and R. H. Scott, Br. J. Pharmacol., 88, 213 (1986).
191. N. R. Newberry and R. A. Nicoll, Nature (London), 308, 405 (1984).
192. A. C. Dolphin, S. M. McGuirk, and R. H. Scott, Br. J. Pharmacol., 97, 263 (1989).
193. D. I. B. Kerr and J. Ong, Current Opinion Neurol. Neurosurg., 4, 566 (1991).
194. W. Froestl, S. J. Mickel, G. von Sprecher, P. J. Diel, R. G. Hall, L. Maier, D. Strub, V. Melillo, P. A. Baumann, R. Bernasconi, C. Gentsch, K. Hauser, J. Jaekel, G. Karlsson, K. Klebs, L. Maitre, C. Marescaux, M. F. Pozza, M. Schmutz, M. W. Steinmann, H. van Riezen, A. Vassout, C. Mondadori, H.-R. Olpe, P. C. Waldmeier, and H. Bittiger, J. Med. Chem., 38, 3313 (1995).
195. P. K. Kadaba, Biomed. Pharmacother., 50, 163 (1996).
196. P. K. Kadaba, U.S. Patent 4,820,721, April, 1988.
197. C. A. Drew and G. A. R. Johnston, J. Neurochem., 58, 1087 (1992).
198. G. Mathews, G. Ayoub, and R. Heidelberger, Soc. Neurosci. Abstr., 17, 900 (1991).
199. G. R. Cutting, L. Lu, B. O'Hara, L. M. Kasch, D. Donovan, S. Shimada, S. E. Antonarakis, W. B. Guggino, G. R. Uhl, and H. H. Kazazian, Proc. Natl. Acad. Sci., 88, 2673 (1991).
200. G. A. R. Johnston, D. R. Curtis, P. M. Beart, C. J. A. Garne, R. M. McCulloch, and B. Twitchin, J. Neurochem., 24, 157 (1975).
201. C. A. Drew, G. A. R. Johnston, and R. P. Weatherby, Bicuculline-insensitive GABA receptors: Studies on the binding of (-)-baclofen to rat cerebellar membranes (1984).
202. A. H. Kurland and T. R. Browne, Clin. Neuropharmacol., 17, 560 (1994).
203. J. D. Wood and S. J. Peesker, Can. J. Physiol. Pharmacol., 54, 534 (1976).
204. I. O. Edafiogho, K. R. Scott, J. A. Moore, V. A. Farrar, and J. M. Nicholson, J. Med. Chem., 34, 387 (1991).
205. M. N. Iskander, P. R. Andrews, D. A. Winkler, R. I. Brinkworth, C. D. Paola, S. Cavell, and J. Issa, Eur. J. Med. Chem., 26, 129 (1991).
206. I. E. Leppick, Epilepsia, 35 (suppl. 4), S29 (1994).
207. P. Krogsgaard-Larsen, in Specific GABA Receptor Agonist and Uptake Inhibitors: Design, Development, and Structure-Activity Studies, adl's Forlag, Copenhagen, 1980.
208. A. Schousboe, P. Thorbek, L. Hertz, and P. Krogsgaard-Larsen, J. Neurochem., 33, 181 (1979).
209. Y. P. Li and J. B. Lombardini, Brain Res., 510, 147 (1990).
210. M. R. Pavia, S. J. Lobbestael, D. Nugiel, D. R. Mayhugh, V. E. Gregor, C. P. Taylor, R. D. Schwarz, L. Brahce, and M. G. Vartanian, J. Med. Chem., 35, 4238 (1992).
211. K. E. Andersen, C. Braestrup, F. C. Gronwald, A. S. Jorgensen, E. B. Nielsen, U. Sonnewald, P. O. Sorensen, P. D. Suzdak, and L. J. S. Knutsen, J. Med. Chem., 36, 1716 (1993).
212. C. F. Baxter and E. Roberts, J. Biol. Chem., 233, 1135 (1958).
213. R. A. E. Bakay and A. B. Harris, Brain Res., 206, 387 (1981).
214. K.G. Lloyd, C. Munari, L. Bossi, C. Stoeffels, J. Talairach, and P. L. Morselli, Biochemical Evidence for the Alterations of GABA-mediated Synaptic Transmission in Pathological Brain Tissue from Epileptic Patients, in Neurotransmission, Seizures, Epilepsy, P. L. Morselli, W. Loescher, and K. G. Lloyd, Eds., Raven Press, New York, 1981, pp. 325-338.
215. R. B. Silverman, R. Andruszkiewicz, S. M. Nanavati, C. P. Taylor, and M. G. Vartanian, J. Med. Chem., 34, 2295 (1991).
216. W. R. Martin, C. G. Eades, J. A. Thompson, R. E. Happier, and P. Gilbert, J. Pharmacol. Exp. Ther., 197, 517 (1976).
217. J. M. Walker, W. D. Bowen, F. O. Walker, R. R. Matsumoto, B. de Costa, and K. C. Rice, Pharmacol. Rev., 42, 355 (1990).
218. R. Quirion, W. D. Bowen, Y. Itzhak, J. L. Junien, J. M. Musacchio, R. B. Rothman, T.-P. Su, S. W. Tam, and D. P. A. Taylor, Trends Pharmacol. Sci., 13, 85 (1992).
219. S. D. Wyrick and R. G. Booth, Drugs Future, 20, 1033 (1995).
220. T.-P. Su, Eur. J. Biochem., 200, 633 (1991).
221. S. B. Hellewell and W. D. Bowen, Brain Res., 527, 244 (1990).
222. S. Iyengar, S. Mick, V. Dilworth, J. Michel, T. S. Rao, J. M. Farah, and P. L. Wood, Neuropharmacology, 29, 299 (1990).
223. X. Pascaud, J. P. Defaux, C. Roze, and J. L. Junien, J. Pharmacol. Exp. Ther., 255, 1354 (1990).
224. X.-Z. Wu, J. A. Bell, C. E. Spivak, E. D. London, and T.-P. Su, J. Pharmacol. Exp. Ther., 257, 351 (1991).
225. W. D. Bowen, S. B. Hellewell, and K. A. McGarry, Eur. J. Pharmacol., 163, 309 (1989).
226. J. M. Musacchio, M. Klein, and J. J. Paturzo, Mol. Pharmacol., 35, 1 (1989).
227. D. W. Choi, S. Peters, and V. Viseskul, J. Pharmacol. Exp. Ther., 242, 713 (1987).
228. R. R. Matsumoto and J. M. Walker, Eur. J. Pharmacol., 158, 161 (1988).
229. R. R. Matsumoto and J. M. Walker, Soc. Neurosci. Abstr., 14, 202 (1988).
230. F. P. Monnet, G. Debonnel, J. L. Junien, and C. de Montigny, Eur. J. Pharmacol., 179, 441 (1990).
231. F. J. Roman, X. Pascaud, O. Duffy, and J. L. Junien, in NMDA and Related Agents: Biochemistry, Pharmacology and Behavior, T. Kameyama, T. Nabeshima, and E. F. Domino, Eds., NPP Book, Ann Arbor, MI, 1991, pp. 211-218.
232. B. J. Vilner, B. R. de Costa, and W. D. Bowen, J. Neurosci., 15, 117 (1995).
233. F. P. Monnet, G. Debonnel, and C. de Montigny, J. Pharmacol. Exp. Ther., 261, 123 (1992).
234. G. M. Gonzalez-Alvear and L. L. Werling, J. Pharmacol. Ther., 271, 212 (1994).
235. P. C. Contreras, D. M. Ragan, M. E. Bremer, T. H. Lanthorn, N. M. Gray, S. Iyengar, A. E. Jacobson, K. C. Rice, and B. R. de Costa, Brain Res., 546, 79 (1991).
236. T. R. Deshmukh and P. K. Kadaba, Med. Chem. Res., 3, 223 (1993).
237. S. N. Calderon, S. Izenwasser, B. Heller, J. S. Gutkind, M. V. Mattson, T.-P. Su, and A. H. Newman, J. Med. Chem., 37, 2285 (1994).
238. R. B. Rothman, A. Reid, A. Mahboubi, C. Kim, B. R. de Costa, A. E. Jacobson, and K. C. Rice, Mol. Pharmacol., 39, 222 (1991).
239. A. P. Jeanjean, M. Mestre, J. M. Maloteaux, and P. M. Laduron, Eur. J. Pharmacol. 241, 111 (1993).
240. R. R. Matsumoto, M. K. Hemstreet, N. Lai, A. Thurkauf, B. R. de Costa, K. C. Rice, S. B. Hellewell, W. D. Bowen, and J. M. Walker, Pharmacol. Biochem. Behav., 36, 151 (1990).
241. J. M. Walker, W. D. Bowen, S. L. Patrick, W. E. Williams, S. W. Mascarella, X. Bai, and F.I.A. Carroll, Eur. J. Pharmacol., 231, 61 (1993).
242. C. M. Bertha, B. J. Vilner, M. V. Mattson, W. D. Bowen, K. Becketts, H. Xu, R. B. Rothman, J. L. Flippen-Anderson, and K. C. Rice, J. Med. Chem., 38, 4776 (1995).
243. R. G. Booth, S. D. Wyrick, R. J. Baldessarini, N. S. Kula, A. M. Myers, and R. B. Mailman, Mol. Pharmacol., 44, 1232 (1993).
244. S. D. Wyrick, R. G. Booth, A. M. Myers, C. E. Owens, N. S. Kula, R. J. Baldessarini, A. McPhail, and R. B. Mailman, J. Med. Chem., 36, 2542 (1993).
245. A. M. Myers, P. S. Charifson, C. E. Owens, N. S. Kula, A. T. McPhail, R. J. Baldessarini, R. G. Booth, and S. D. Wyrick, J. Med. Chem., 37, 4109 (1994).
246. M. H. Aprison, "Glycine as a neurotransmitter," in Psychopharmacology: A Generation of Progress, M. A. Lipton, A. DiMascio, and K. F. Killam, Eds., Raven Press, New York, 1978, pp. 333-346.
247. R. A. Nicoll, "Physiological Studies on Amino Acids and Peptides as Prospective Transmitters in the CNS," in Psychopharmacology: A generation of Progress, M. A. Lipton, A. DiMascio, and K. F. Killam, Eds., Raven Press, New York, 1978, pp. 103-118.
248. European Patent PCT WO/96/18650.
249. W. N. Chan, J. M. Evans, M. S. Hadley, H. J. Herdon, J. C. Jerman, H. K. A. Morgan, T. O. Stean, M. Thompson, N. Upton, and A. K. Vong, J. Med. Chem., 39, 4537 (1996).
250. K. R. Scott, G. O. Rankin, J. P. Stables, M. S. Alexander, I. O. Edafiogho, V. A. Farrar, K. R. Kolen, J. A. Moore, L. D. Sims, and A. D. Tonnu, J. Med. Chem., 38, 4033 (1995).
251. D. A. Coulter, J. R. Hugenard, and D. A. Prince, Neurosci. Lett. (1989).
252. P. Ehrlich, Ber. Dtsch. Chem. Ges., 42, 17 (1909).
253. M. Williams, Ann. Rep. Med. Chem., 27, 1 (1992).
254. NINDS, Maximizing Human Potential, Decade of the Brain, 1990-2000, NINDS, Bethesda, MD, 1991.
255. A. B. Young and G. E. Fagg, Trends Pharmacol. Sci., 11, 126 (1990).
256. J. P. Snyder, Med. Res. Rev., 11, 641 (1991).
257. J. W. Erickson and S. W. Fesik, Ann. Rep. Med. Chem., 27, 271 (1992).
258. W. H. Moos, G. D. Green, and M. R. Pavia, Ann. Rep. Med. Chem., 28, 315 (1993).
259. J. Hodgson, Biotechnology, 10, 1093 (1992).
260. B. S. Meldrum and M. Williams, Eds., Current and Future Trends in Anticonvulsant, Anxiety and Stroke Therapy, Wiley, New York, 1990.